Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NormOxys names first chief medical officer

This article was originally published in Scrip

Executive Summary

NormOxys, a US biotechnology company developing small-molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, has appointed Dr David Clark as its first chief medical officer. He will manage the company's clinical affairs, including the development of its lead product candidate, OXY111A, which is expected to enter clinical trials in the first quarter of 2010. Dr Clark, who has more than 12 years' pharmaceutical drug development experience, previously led clinical teams while working in the clinical development division at Pfizer.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC006112

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel